Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | BRD2 | P25440 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 2/20 | 0.35 |
| ▸ | KLK1 | P06870 | 2/20 | 0.35 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329107 | 1.00 | RET (0.44) | RETKLKB1AKT2EGFRBRD4 | |
| SCHEMBL6329081 | 0.92 | RET (0.42) | RETAKT2EGFRBRD4BRD2 | |
| SCHEMBL6329067 | 0.92 | RET (0.42) | RETAKT2EGFRBRD4BRD2 | |
| SCHEMBL6337430 | 0.90 | RET (0.41) | RETEGFRBRD4BRD2CHEK1 | |
| SCHEMBL6337435 | 0.90 | RET (0.41) | RETEGFRBRD4BRD2CHEK1 | |
| SCHEMBL7475197 | 0.90 | RET (0.41) | RETEGFRBRD4BRD2CHEK1 | |
| SCHEMBL6330783 | 0.89 | RET (0.44) | RETAKT2EGFRBRD4CHEK1 | |
| SCHEMBL6330792 | 0.89 | RET (0.44) | RETAKT2EGFRBRD4CHEK1 | |
| SCHEMBL6336573 | 0.88 | RET (0.43) | RETEGFRBRD4BRD2CHEK1 | |
| SCHEMBL6336574 | 0.88 | RET (0.43) | RETEGFRBRD4BRD2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1212318-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma KG (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016130-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | RET 154/4885KLKB1 4031/4885AKT2 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.